SLC16A3 and cancer: Moreover, targeting MCT1 and MCT4 with syrosingopine in cell models from different cancer types, Bejamin et al. (186) found an increase in intracellular lactate in HeLa cells, and the liver mouse model showed reduction in lactate concentration in nodules after syrosingopine treatment.